BioCentury | May 28, 2020
Distillery Therapeutics

Epigenetic enzyme Tet1 as osteoarthritis target

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Inhibiting Tet1, an epigenetic enzyme that methylates cytosine, could treat osteoarthritis. In patient-derived chondrocytes, an shRNA against Tet1 reduced mRNA levels of two disease markers, MMP3 and MMP13, as...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Epigenetic enzyme Tet3 as target in liver fibrosis

...Liver fibrosis Inhibiting the DNA demethylase Tet3 could treat liver fibrosis. Liver tissue levels of Tet3...
...fibrotic livers than those with non-fibrotic livers. In mice with liver fibrosis, an siRNA against Tet3...
...include identifying and testing siRNAs or small molecules against Tet3 in models of fibrosis. TARGET/MARKER/PATHWAY: Tet methylcytosine dioxygenase 3 (Tet3)...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Jun 22, 2018
Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
BioCentury | May 30, 2018
Preclinical News

Tet2 disruption improves Kymriah efficacy

In a Nature study , researchers at the University of Pennsylvania identified a patient with an enhanced response to CAR T therapy Kymriah tisagenlecleucel, and suggested targeting the epigenome by inhibiting Tet2 could improve the efficacy...
BioCentury | Apr 24, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with bone-specific overexpression of VEGF-C could be used to screen therapies to treat Gorham-Stout disease. Generation of the model involves crossing a mouse line, in which expression of a tetracycline transactivator...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest that promoting the expression of Tet2 could help treat age-related neurodegeneration. In a mouse model of age-related neurodegeneration, intrahippocampal injection of Tet2 encoded in a lentiviral vector increased associative fear...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Dec 11, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Inducible Tet repressor protein (TetR)-RNA interaction system for control of Plasmodium falciparum gene expression A system for controlling P. falciparum gene expression could be...
Items per page:
1 - 10 of 18